Organigram (OGI) Q2 2026 earnings review
Core Business Contracts as Organigram Buys Its Way to Growth
Organigram's organic turnaround hit a wall in Q2. Net revenue fell 9% YoY and 6% sequentially, driven by steep underperformance in vapes and infused pre-rolls amid slower industry growth. This volume loss immediately squeezed profitability, with Adjusted EBITDA collapsing 82% to just $0.9 million. To mask the core organic deceleration, management finalized the massive Sanity Group acquisition, drastically hiking FY26 revenue guidance to over $350 million. Furthermore, a quiet $5.8 million impairment on the U.S. hemp business effectively closed the book on past management's rosy narrative about American expansion.
🐂 Bull Case
The acquisition of Germany's Sanity Group instantly injects approximately €25 million in quarterly revenue, providing a massive scale-up to the higher-margin European segment and entirely saving FY26 top-line guidance.
The Moncton facility achieved a record 32,000 kg harvest (+56% YoY) with highest-ever average THC potency, pointing to significant underlying improvements in agricultural unit economics.
🐻 Bear Case
Domestic sales are visibly shrinking amidst intense competition in vapes and pre-rolls. Revenue reversed its growth trend entirely, dropping 9% YoY and taking gross margins down with it.
SG&A expenses jumped to 39% of net revenue, destroying operating leverage. The company is spending more to sell fewer products in a tightening Canadian market.
⚖️ Verdict: 🔴
Bearish. The core Canadian business is visibly shrinking, and the abrupt $5.8M impairment on the U.S. hemp business shatters previous management narratives. While the Sanity Group acquisition artificially inflates FY26 guidance, masking organic decay with purchased revenue is not a sustainable path to real free cash flow.
Key Themes
The Sanity Group Lifeboat
With domestic sales stalling, the acquisition of Germany's Sanity Group is the sole catalyst rescuing the FY26 narrative. Expected to add approximately €25 million in average quarterly revenue, it single-handedly allowed management to raise FY26 revenue guidance from '>$300M' to '>$350M'. This immediately transforms Organigram's geographic mix but introduces massive cross-border integration risks.
Core Product Segments Decelerating
The Canadian recreational engine has sputtered. Net revenue declined 9% YoY to $59.8M, reversing the aggressive sequential growth seen throughout FY25. Management pointed directly to 'underperformance in vapes and temporary challenges in infused pre-roll production' exacerbated by slower industry macro growth. Organigram is rapidly losing ground in the exact derivative categories it spent heavily (via Motif Labs) to dominate.
U.S. Hemp Ambitions Collapse
Less than two years after aggressively touting its entry into the '$4 billion TAM' U.S. hemp-derived beverage market (via the Collective Project acquisition), the company recorded a $5.8 million impairment loss on its U.S. hemp business. This directly contradicts the highly bullish narrative sold to investors over the past three quarters and marks an abrupt failure to execute in the American market.
Scientific Breakthroughs & Cultivation Efficiencies
Cultivation metrics remain the brightest spot operationally. The Moncton facility achieved a record 32,000 kg harvest (+56% YoY). Backed by specific technological innovation—the launch of two new powdery mildew-resistant cultivars resulting from advanced genetic marker identification—Organigram is aggressively insulating its crop yields and lowering its per-gram production costs.
Profitability Squeeze & Rising SG&A
Operational deleverage struck hard this quarter. Adjusted gross margin compressed to 31% from 33% YoY due to an unfavorable product mix and higher product returns. Simultaneously, SG&A increased to $23.6M (39% of net revenue, up from 34%), driven by promotional spending that failed to translate into top-line growth.
Australian Market Expansion
Organigram is successfully diversifying its export mix beyond whole flower. The company launched 10 new SKU variants of vapes and gummies in Australia under the BOXHOT and Edison brands, targeting over 4,000 pharmacies. Expanding higher-margin derivative products into international medical markets is a critical offset to domestic weakness.
Quality Control Headwinds in Export Channel
International Revenue was flat YoY at $6.1M, failing to generate anticipated growth because of an 'elevated proportion of product that did not meet international specifications.' In highly regulated markets like Europe and Australia, spec failures destroy margins and strain partner relationships. This execution lapse must be corrected before the Sanity Group volume scales up.
Other KPIs
Stable. While still burning cash, it marks a stark improvement from the -$23.1M outflow in 25Q2. Working capital investments and CapEx are finally normalizing, though the breakeven guidance for FY26 looks tenuous given the severe organic EBITDA collapse this quarter.
A glaring fundamental disconnect: the company reported a record 32,000 kg harvest while simultaneously posting a 9% YoY sales decline. This points to a massive impending inventory build. If demand does not rapidly accelerate to absorb this excess, future inventory write-downs are highly probable.
Guidance
Accelerating. The company raised its target from '>$300 million' strictly due to the Sanity Group acquisition (expected to add €25M quarterly). With H1 organic revenue sitting at $123M, the base business is severely lagging, meaning the new German acquisition will have to do all the heavy lifting in H2.
Accelerating. H1 FY26 has generated only $6.1M combined. Achieving >$21.9M implies a massive step-up in H2, relying heavily on immediate accretive margins from Sanity Group and a dramatic, sudden reversal of the Q2 domestic margin collapse.
Decelerating. Pre-acquisition, management promised 'positive Free Cash Flow.' Integrating Sanity Group has evidently pushed out cash generation targets, as the company absorbs acquisition costs and the working capital demands of its new European footprint.
Key Questions
Inventory Write-Down Risks
With a record 32,000 kg harvest but declining sequential and YoY sales, how severe is the current inventory buildup, and are there impending write-downs if this volume cannot be moved organically?
U.S. Hemp Strategy Reversal
Regarding the sudden $5.8M impairment on the U.S. hemp business, does this signal a complete operational exit from the U.S. market, or merely a write-down of past goodwill?
International Spec Failures
You noted elevated international shipments that failed to meet specifications. What precise operational or compliance changes are being made to fix this before Sanity Group volumes hit the supply chain?
Sticky SG&A Costs
SG&A rose to 39% of net revenue despite falling sales. How much of this cost base is structurally sticky, and what is the realistic target ratio post-Sanity Group integration?